Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET
Company Participants
Diane Weiser - SVP of Corporate Communications and IR
Robert Blum - President and CEO
Fady Malik - EVP of R&D
Andrew Callos - EVP and Chief Commercial Officer
Stuart Kupfer - SVP and Chief Medical Officer
Robert Wong - VP and CAO
Ching Jaw - SVP and CFO
Conference Call Participants
Carter Gould - Barclays
Joe Pantginis - H.C. Wainwright
Salim Syed - Mizuho Securities
Sean McCutcheon - Raymond James
Justin Kim - Oppenheimer
Pete Stavropoulos - Cantor Fitzgerald
Serge Belanger - Needham & Company
Operator
Good afternoon. And welcome, ladies and gentlemen, to Cytokinetics' First Quarter 2022 conference call. At this time, I’d like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the c’s request, we will open the call for questions-and-answers after the presentation. [Operator Instructions].
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with a brief overview of the quarter and recent developments. Fady Malik, EVP of R&D, will then provide updates related to omecamtiv mecarbil and aficamten; Andrew Callos, EVP and Chief Commercial Officer, will discuss commercialization planning activities for omecamtiv mecarbil and our franchise strategy related to aficamten; Stuart Kupfer, SVP and Chief Medical Officer will provide an update on reldesemtiv. Robert Wong, VP and Chief Accounting Officer, will provide a financial overview for the past quarter. And Ching Jaw, SVP and Chief Financial Officer, will discuss our financial outlook and corporate development strategies. Finally, Robert Blum will provide closing comments and review expected key milestones for 2022.
Please note that portions of the following discussion including our responses to questions contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our first quarter 2022 financial results filed on Form 8-K today. We undertake no obligation to update any forward-looking statements after this call.